By continuing to use our site, you consent to the processing of cookies, user data (location information, type and version of the OS, the type and version of the browser, the type of device and the resolution of its screen, the source of where the user came from, from which site or for what advertisement, language OS and Browser, which pages are opened and to which buttons the user presses, ip-address) for the purpose of site functioning, retargeting and statistical surveys and reviews. If you do not want your data to be processed, please leave the site.

The Voice of People With Breast Cancer

What breast cancer drugs are available in Canada

MedSearch

Generic Name

Trastuzumab deruxtecan

Brand Name

Enhertu
HER2+
Stage IV (metastatic)
Targeted Therapy
AstraZeneca Canada Inc.
Injectable
British Columbia, Quebec
Alberta, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Northwest Territories, Nunavut, Ontario, Prince Edward Island, Saskatchewan, Yukon
No
Listed on Provincial Drug Formulary

For the treatment of unresectable or metastatic locally advanced breast cancer slightly overexpressing the human epidermal growth factor receptor type 2 (HER2).

Approved for reimbursement in Quebec (with condition of reduced price, and supervised use).

Yes - Open

To support patients with unresectable or metastatic breast cancer who have been prescribed Enhertu, AstraZeneca Canada (AstraZeneca) has opened a Patient Support Program (PSP), effective July 12, 2021. Patients enrolled in the PSP will have access to educational resources, reimbursement navigation support, and for those with private insurance, co-payment towards the cost of the drug (up to 20 percent). The PSP will also offer a free drug program which will provide financial support for Enhertu at 100% for eligible patients.

Components of the program include the following:
•    All eligible patients enrolled in the free drug component of the PSP by end of day August 1, 2023 will continue to receive free drug through the PSP until disease progression, or public reimbursement, whichever is earlier.              
•    After August 1, 2023, all NEW eligible patients enrolled in the PSP will still have access to educational resources, reimbursement navigation, infusion support and co-payment support toward the cost of Enhertu (up to 20%). The free drug component of the Enhertu DESTINY-Breast03 PSP will no longer be available. 

If you have questions you can contact the PSP directly at the following:

Fax: 1-877-280-6221
Email: enrollment@azoncologypsp.ca
Phone: 1-877-280-6208

Health Canada Drug Monograph

FAQ's